Anti-fungal Drugs Market Research 2019-2024; Regional Industry Segment by Production, Consumption, Revenue and Growth Rate

(The Express Wire via Comtex)

Anti-fungal Drugs Market share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Global “Anti-fungal Drugs Market” is an overview of the global market is provided with prime focus on factors boosting and hampering market. This will help investors get a clear understanding on which aspects to focus on and how to economically support the market globally. The impact of prevailing regulatory scenario on both regional and worldwide Anti-fungal Drugs market is provided detail in this report.

Market Overview:

  • The major factors augmenting the growth of the anti-fungal drugs market include the increasing awareness about the myriad fungal infections, increasing number of antifungal drugs available over-the-counter (OTC), and rising consumption of anti-fungal drugs in developing regions for a variety of medical conditions.
  • With the rising popularity of over-the-counter (OTC) drugs, many patients prefer OTC drugs over obtaining a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, as these infections can be treated by OTC drugs, owing to their ease of availability. According to the Consumer Healthcare Products Association, more than 81% of adults use OTC medicines as their first response to minor ailments. The increased usage of OTC drugs has further contributed to the rise in anti-fungal drug sales over the years. Many OTC anti-fungal creams, ointments, and tablets are available worldwide. With many drugs still in the pipeline, OTC drugs are estimated to conquer the existing anti-fungal drugs market over the forecast period. The anti-fungal drugs market is expected to grow at a steady pace owing to the rising research and development activities. When a harmful fungal infection is detected in a patient, OTC drugs are sometimes used to minimize the fungal effect, until consulted by a doctor. Considering all the factors, OTC drugs play a crucial role in driving the growth of the global anti-fungal drugs market.

Get a Sample Copy of the Report - https://www.absolutereports.com/enquiry/request-sample/14099134

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

  • Abbott Laboratories
  • Astellas Pharma, Inc.
  • Bayer AG
  • GlaxoSmithKline Plc
  • Glenmark
  • Kramer Laboratories
  • Merck and Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • SCYNEXIS, Inc.

Scope of the Report:

  • As per the scope of this report, anti-fungal drugs refer to the drugs used/prescribed for the treatment of diseases caused by fungi. The report covers (but is not limited to) drugs used/prescribed in aspergillosis, dermatophytosis, and candidiasis. The types of drugs covered (but are not limited to) in this report are echinocandins, azoles, polyenes, and allylamines. The definitions for individual segments have been provided in the respective segments.

Market Dynamics:

  • Drivers: (Developing regions and growing markets)
  • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
  • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

The report provides key statistics on the market status of the Anti-fungal Drugs Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Anti-fungal Drugs.

For More Information or Query or Customization Before Buying, Visit at - https://www.absolutereports.com/enquiry/pre-order-enquiry/14099134

Key questions answered in the report include:

  • What will the market size and the growth rate be in 2024?
  • What are the key factors driving the global Anti-fungal Drugs market?
  • What are the key market trends impacting the growth of the global Anti-fungal Drugs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global Anti-fungal Drugs market?
  • What are the market opportunities and threats faced by the vendors in the global Anti-fungal Drugs market?
  • Trending factors influencing the market shares of the relevant regions.
  • What are the key outcomes of the five forces analysis of the global Anti-fungal Drugs market?

Key Market Trends:

Azoles Segment under Drug Type Segmentation is expected to be the Fastest Growing Market over the Forecast Period

Anti-fungal drug research is gaining momentum, owing to the development of new antifungal drugs using the azole group. Azoles are synthetic and semi-synthetic compounds, widely used for superficial and invasive fungal infections. The drugs are used to treat thrush, yeast infection, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, nail fungus, fungal infections, systemic mycosis, and seborrheic dermatitis. The azole anti-fungal group includes two classes, namely the triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and the imidazoles (ketoconazole). Triazoles have a broad range of applications in the treatment of superficial and systemic fungal infections. The azole group offers a broad spectrum of activity and improved safety levels. The drugs have fewer adverse effects, less serious drug interactions, and improved absorption and distribution properties. The aforementioned benefits of azoles have contributed toward their dominance over other segments. The azoles are currently the most widely used and studied class of antifungal agents. The drugs are available in different formulations (oral tablet, oral capsule, cream, dandruff shampoo, sterile IV solution, lotion, vaginal cream, and tablet). The advancements and innovations in such potential drugs fuel the competitiveness of the pharmaceutical market. Sales of both the established agents and newly launched anti-fungal agents are significant. The issue with antifungal drug resistance has prompted further investigations of the underlying molecular mechanisms. Increased resistance is being observed amongst the Candida and Aspergillus species, particularly to azoles, which is believed to be driven by the use of azoles in agriculture. Increasing drug resistance is anticipated to provide an opportunity for other drug classes to capture the market.

North America is expected to account for the Largest Market Share in the Global Market

Fungal diseases in the United States have presented challenges to the healthcare authorities in the country. People across the world, including in the United States, have developed resistance to the available medicines. According to the Centers for Disease Control and Prevention (CDC), resistance to certain types of Candida (which happens to be the most common cause of healthcare-associated bloodstream infections in the United States) has been noticed. Approximately 7% of all the Candida bloodstream isolates tested at CDC are resistant to fluconazole. This observation has remained fairly constant over the last two decades. However, echinocandin resistance has been on the rise. In addition, the incidences of multi-drug resistance have increased in the country. Moreover, thirteen cases of Candida auris (which can cause invasive infections and is resistant to anti-fungal drugs) have been identified in the United States. According to the CDC, out of the thirteen, seven of the cases occurred between May 2013 and August 2016. The immunocompromised, aged population is on the rise in the United States. There were close to 46 million people aged 65 years and above in 2015. The population is expected to double (over 98 million) by 2060. This will represent about 24% of the total population in the country. This population is more susceptible to chronic diseases, such as cancer, thereby compromising the immune system. Thus, the population would be more susceptible to other diseases, like fungal diseases. The increasing incidences of resistance and immunocompromised population have been a major concern for the government. This provides an opportunity for pharmaceutical players in the country to develop novel and more effective drugs for fungal diseases.

Purchase this Report (Price 4250 USD for single user license) - https://www.absolutereports.com/purchase/14099134

Study objectives of Anti-fungal Drugs Market Report:

  • To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the Anti-fungal Drugs market
  • To provide insights into factors influencing and affecting market growth
  • To provide historical, current, and forecast revenue of market segments based on material, type, design, and end user
  • To provide historical, current, and forecast revenue of market segments and sub-segments with respect to regional markets and key countries
  • To provide strategic profiling of key players in the market, comprehensively analyzing their market shares, core competencies, and drawing a competitive landscape for the market
  • To provide economic factors, technology trends, and market trends that influence the global Anti-fungal Drugs market

Detailed TOC of Anti-fungal Drugs Market Report 2019-2024:

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about the Myriad Fungal Infections
4.2.2 Increasing Number of Antifungal Drugs as Over-The-Counter (OTC)
4.2.3 Rising Consumption of Anti-fungal Drugs in Developing Regions for a Variety of Medical Conditions
4.3 Market Restraints
4.3.1 Medical Conditions
4.3.2 Increasing Resistance to Antifungal Drugs
4.3.3 Side Effects of Antifungal Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Echinocandins
5.1.2 Azoles
5.1.3 Polyenes
5.1.4 Allylamines
5.1.5 Other Drug Type
5.2 By Indication
5.2.1 Aspergillosis
5.2.2 Dermatophytosis
5.2.3 Candidiasis
5.2.4 Other Indications
5.3 By Dosage Forms
5.3.1 Powder
5.3.2 Ointments
5.3.3 Tablets
5.3.4 Other Dosage Forms
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Astellas Pharma, Inc.
6.1.3 Bayer AG
6.1.4 GlaxoSmithKline Plc
6.1.5 Glenmark
6.1.6 Kramer Laboratories
6.1.7 Merck and Co., Inc.
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 SCYNEXIS, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [email protected]

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Anti-fungal Drugs Market Research 2019-2024; Regional Industry Segment by Production, Consumption, Revenue and Growth Rate